Cargando…
The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
Two hundred patients with node positive stage II breast cancer were randomised to four groups after radical mastectomy and axillary evacuation: (1) Postoperative radiotherapy, (2) Adjuvant chemotherapy with eight courses of CAFt (cyclophosphamide 500 mg m-2 + doxorubicin 40 mg/m-2 + ftorafur 20 mg k...
Autores principales: | Blomqvist, C., Tiusanen, K., Elomaa, I., Rissanen, P., Hietanen, T., Heinonen, E., Gröhn, P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978025/ https://www.ncbi.nlm.nih.gov/pubmed/1457360 |
Ejemplares similares
-
Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.
por: Saarto, T., et al.
Publicado: (1997) -
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids
por: Vehmanen, L, et al.
Publicado: (2004) -
NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
por: Yeo, Winnie, et al.
Publicado: (2022) -
Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.
Publicado: (1988) -
Proceedings: A comparison of the cell killing in the mouse after exposure to ftorafur and to 5-fluorouracil.
por: Van Putten, L. M., et al.
Publicado: (1974)